Oncogene products represent potential targets of tumor vaccines.
Tuttle
T M
TM
Department of Surgery, Park Nicollet Clinic, Minneapolis, MN 55416, USA.
D000818:Animals; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins / Q000235:genetics / Q000276:immunology*; D016044:Fusion Proteins, bcr-abl / Q000235:genetics / Q000276:immunology*; D005784:Gene Amplification; D011905:Genes, ras / Q000235:genetics; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D051379:Mice; D009363:Neoplasm Proteins / Q000235:genetics / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000276:immunology*
D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D016044:Fusion Proteins, bcr-abl; D009363:Neoplasm Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D016159:Tumor Suppressor Protein p53; C493956:CDKN1A protein, human; C493957:Cdkn1a protein, mouse